Headlands Research Expands Presence in the Caribbean with Acquisition of CMRCenter

Headlands Research Expands in the Caribbean with CMRCenter Acquisition

In a significant move, Headlands Research has recently announced the acquisition of CMRCenter, a prominent clinical research site based in San Juan, Puerto Rico. This acquisition not only widens Headlands' presence but also extends their comprehensive network to 22 sites across the United States, Canada, and Puerto Rico. With this expansion, biopharma sponsors are set to enjoy a streamlined, single-contract access to one of the largest Hispanic patient populations under the oversight of the FDA, thereby facilitating a faster enrollment process for critical vaccine, CNS, and specialty studies.

Headlands Research CEO, Kyle Burtnett, expressed enthusiasm about this acquisition, stating, “CMRC's proven performance in CNS, vaccine, and specialty trials, combined with its deep ties to Puerto Rico's diverse, FDA-regulated patient community, gives sponsors a seamless path to high-quality enrollment in a priority market.” This partnership is poised to leverage the strengths of both organizations, combining CMRC's expertise and community relations with Headlands' extensive resources and best practices, thereby speeding up the delivery of much-needed therapies to patients.

Founded under the leadership of Carmen D. Navarro, CMRCenter has established a solid record in clinical research, backed by an elite team of investigators, including Dr. Carmen C. Deseda. CMRC’s bilingual staff and profound understanding of Puerto Rico’s medical and cultural landscape enable it to engage efficiently with a participant database of over 10,000. Their impressive recruitment strategy has led to consistently surpassing enrollment targets for both pediatric and adult Phase II–IV trials, boasting a remarkable retention rate of 90% across various studies, including those related to vaccines, early Alzheimer's disease, rheumatology, and migraines.

Navarro stated, “CMRC has been dedicated to advancing the well-being of Puerto Ricans through quality, patient-centric clinical research. By joining the Headlands Research site network, we expand that commitment, offering our community earlier access to innovative therapies, broadening the therapeutic areas we serve, and adding Puerto Rico's diverse voice to global studies that will benefit patients everywhere.”

With this acquisition, CMRC is well-positioned to scale its efforts and enhance its impact, thanks to Headlands’ centralized quality systems, technology investments, and collaborative network that promotes knowledge sharing. This collaboration is expected to expedite the introduction of innovative therapies, thus significantly benefitting patients not only in Puerto Rico but across the globe.

Headlands Research continues its mission to improve lives by advancing innovative medical therapies, focusing on factors crucial to successful clinical trials such as large-volume recruitment of diverse and specialty patient populations. With over 5,000 clinical trials successfully completed, the organization is dedicated to maintaining the highest data quality while ensuring trials meet regulatory standards.

For more information about Headlands Research and their commitment to advancing clinical research, visit headlandsresearch.com, or connect with them on LinkedIn for updates on their ongoing initiatives.